Sphingolipid Mediators of Myocardial Pathology
Journal of Lipid and Atherosclerosis
;
: 23-49, 2020.
Artigo
em Inglês
| WPRIM
| ID: wpr-786083
ABSTRACT
Cardiomyopathy is the leading cause of mortality worldwide. While the causes of cardiomyopathy continue to be elucidated, current evidence suggests that aberrant bioactive lipid signaling plays a crucial role as a component of cardiac pathophysiology. Sphingolipids have been implicated in the pathophysiology of cardiovascular disease, as they regulate numerous cellular processes that occur in primary and secondary cardiomyopathies. Experimental evidence gathered over the last few decades from both in vitro and in vivo model systems indicates that inhibitors of sphingolipid synthesis attenuate a variety of cardiomyopathic symptoms. In this review, we focus on various cardiomyopathies in which sphingolipids have been implicated and the potential therapeutic benefits that could be gained by targeting sphingolipid metabolism.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Patologia
/
Esfingolipídeos
/
Técnicas In Vitro
/
Doenças Cardiovasculares
/
Ceramidas
/
Mortalidade
/
Miócitos Cardíacos
/
Receptores de Lisoesfingolipídeo
/
Metabolismo
/
Cardiomiopatias
Tipo de estudo:
Estudo prognóstico
Idioma:
Inglês
Revista:
Journal of Lipid and Atherosclerosis
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS